Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Neu-4752
- Development stage
- Preclinical
- Lead developer
- Neurim Pharmaceuticals
- Modality
- Small Molecules
01
Overview
Neu-4752 is an investigational drug candidate developed by Neurim Pharmaceuticals, an Israeli biotechnology company. Originally designed as a breathing control modulator for the treatment of central and obstructive sleep apnea, the compound demonstrated significant weight-loss properties in preclinical animal models. Studies showed a reduction of up to 25% in body weight over a 28-day period, which was attributed to delayed gastric emptying and a subsequent decrease in appetite. Based on these findings, Neu-4752 is currently being developed for metabolic disorders, specifically obesity and weight management, and remains in the preclinical stage of development.
Beyond the preview
Go deeper on Neu-4752.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neu-4752.